期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

提高CAR-T细胞疗法抗癌活性及安全性的研究进展 被引量：1

Research progress on improving the anti-cancer activity and safety of the CAR-T cells therapy
下载PDF
导出
摘要 经过25年的研究,以嵌合抗原受体(CAR)为基础的细胞治疗目前在治疗恶性肿瘤方面展现了巨大潜力。近几年有大量的相关试验和临床数据被报道,本综述通过对这些数据的对比和分析,讨论如何增强CAR-T细胞疗法对不可切除的恶性肿瘤的治疗效果,也对CAR-T细胞技术在恶性肿瘤临床治疗领域存在的安全问题及解决策略进行概述。 The great potential of cell therapy based on chimeric antigen receptor （CAR） has been demonstrated in the treatment of malignant tumors through 25 years of research. A large number of experimental and clinical data have been repor- ted in recent years. This review compares and analyzes these data to discuss how to enhance the efficacy of CAR-T cell therapy in the treatment of unresectable malignant tumors and to summarize the safety issues and solution strategies of CAR-T cell technology in the treatment of malignant tumors.
作者 夏涌 黄健 钱其军
机构地区 第二军医大学附属东方肝胆外科医院生物治疗科 第二军医大学附属东方肝胆外科医院肝外三科
出处 《药学实践杂志》 CAS 2016年第4期372-376,共5页 Journal of Pharmaceutical Practice
关键词 嵌合抗原受体 过继细胞免疫治疗 肿瘤 chimeric antigen receptor（CAR） adoptive cell immunotherapy tumors
分类号 R73 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Maus MV, Grupp SA, Porter DL, June CH. Antibody-mod- ified T cells: CARs take the front seat forhematologic malig- nancies[J]. Blood, 2014, 123(17) :2625-2635.
  • 2陈杰,王宇环,罗成林,王慧琴,罗晓玲.嵌合抗原受体T细胞介绍及抗肿瘤临床应用[J].中国细胞生物学学报,2014,36(2):228-235. 被引量：12
  • 3张少华,毕经旺.嵌合抗原受体修饰T细胞在恶性肿瘤中的研究进展[J].国际肿瘤学杂志,2014,41(7):495-499. 被引量：2
  • 4Maude SL, Frey N, Shaw PA, etal. Chimeric antigen recep- tor T cells for sustained remissions in leukemia[J]. N Engl J Med,2014,371(16) : 1507-1517.
  • 5徐云云,金润铭.血液肿瘤治疗中嵌合抗原受体基因修饰T淋巴细胞作用[J].中国实用儿科杂志,2013,28(8):626-629. 被引量：3
  • 6Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor positive T cells in patients with neuroblastoma[J]. Blood, 2011,118(23) : 6050- 6056.
  • 7Lamers CH, Sleiifer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target tox- ieity[J]. MolTher,2013,21(4): 904 -912.
  • 8Rizvi NA, Maziares J, Planchard D, etal. Activity and safety of nivolumab, an anti PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non small-cell lung cancer (CheckMate 063) :a phase 2,single-arm trial[J]. Lancet Oncol, 2015, 16(3) : 257-265.
  • 9TumehPC, HarviewCL, YearleyJH, etal. PD1 blockade induces responses by inhibiting adaptive immune resistance [J]. Nature, 2014,515(7528) : 568-571.
  • 10Rozali EN, Hato SV, Robinson BW, et aZ. Programmed death ligand 2 in cancer-induced immune suppression[J]. Clin Dev Immunol,2012,2012: 6563-5640.

二级参考文献147

  • 1张叔人.肿瘤疫苗临床研究现状及启示[J].中华医学杂志,2005,85(46):3307-3310. 被引量：3
  • 2Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors [J].Cun" Opin Immunol, 2009,21:215-223.
  • 3Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Batv virus spe- cific cytotoxic T lymphocytes expressing the anti-CD30zeta arti- ficial chimeric T-cell receptor for immunotherapy of Hodgkin disease [J].Blood,2007,110(7):2620-2630.
  • 4Daly T, Royal RE, Kershaw MH, et al. Recognition of human co- lon cancer by T cells transduced with a chimeric receptor gene [J].Cancer Gene Ther,2000,7:284-291.
  • 5Brentjens R J, Hollyman DR, WeissM, et al. Treatment of chron- ic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial [J].Mol Ther,2010, 18(4) :666-674.
  • 6Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xeno- grafts [ J ]. Clin Cancer Res, 2007, 13 : 5426-5435.
  • 7Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor en- hances in vivo persistence and antitumor efficacy of adoptively transfen'ed T cells [J].Cancer Ras,2006,66:10995-11004.
  • 8Wilkie S, Picco G, Foster J, et al. Retargeting of hmnan T cells to tumor-associated MUC 1 : the evolution of a chimeric antigen receptor [ J ]. J Im,nunol, 2008,180 : 4901-4909.
  • 9Syam T, Xin H, Xianzheng Z, et al. 4-1BB and CI)28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies [J].Human Gene Therapy, 2010,21:75-86.
  • 10Zhao Y, Wang Q J, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling donmins leads to en- hanced survival of transduced T lymphocytes and antitumor ac- tivity [J ] .J Immunol, 2009,183 : 5563-5574.

共引文献27

同被引文献8

引证文献1

药学实践杂志
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部